Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) EBIT Margin: 2010-2025

Historic EBIT Margin for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -10.71%.

  • Heron Therapeutics' EBIT Margin rose 288.00% to -10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 1985.00%. This contributed to the annual value of -7.99% for FY2024, which is 7908.00% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' EBIT Margin is -10.71%, which was down 143.40% from -4.40% recorded in Q2 2025.
  • Heron Therapeutics' EBIT Margin's 5-year high stood at 10.23% during Q4 2024, with a 5-year trough of -269.43% in Q2 2021.
  • Over the past 3 years, Heron Therapeutics' median EBIT Margin value was -13.84% (recorded in 2024), while the average stood at -36.04%.
  • Per our database at Business Quant, Heron Therapeutics' EBIT Margin tumbled by 5,272bps in 2021 and then soared by 19,141bps in 2022.
  • Heron Therapeutics' EBIT Margin (Quarterly) stood at -259.20% in 2021, then soared by 19,141bps to -67.79% in 2022, then soared by 3,793bps to -29.85% in 2023, then spiked by 4,009bps to 10.23% in 2024, then surged by 288bps to -10.71% in 2025.
  • Its EBIT Margin was -10.71% in Q3 2025, compared to -4.40% in Q2 2025 and 8.11% in Q1 2025.